437 related articles for article (PubMed ID: 19537837)
1. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
2. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
3. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
4. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.
Hodder R; Kesten S; Menjoge S; Viel K
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):157-67. PubMed ID: 18044688
[TBL] [Abstract][Full Text] [Related]
10. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
11. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.
Donohue JF; van Noord JA; Bateman ED; Langley SJ; Lee A; Witek TJ; Kesten S; Towse L
Chest; 2002 Jul; 122(1):47-55. PubMed ID: 12114338
[TBL] [Abstract][Full Text] [Related]
12. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
Karner C; Cates CJ
Cochrane Database Syst Rev; 2012 Apr; 4(4):CD008989. PubMed ID: 22513969
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Rabe KF; Timmer W; Sagkriotis A; Viel K
Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.
Tashkin D; Kesten S
Chest; 2003 May; 123(5):1441-9. PubMed ID: 12740259
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Cope S; Zhang J; Williams J; Jansen JP
BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
[TBL] [Abstract][Full Text] [Related]
18. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
20. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
